Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 2/20 | 0.44 |
| ▸ | FBP1 | P09467 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | IGF2R | P11717 | 2/20 | 0.36 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.36 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12899782 | 0.87 | PPARD (0.44) | PPARDFBP1TSHRIGF2RAMDHD2 | |
| SCHEMBL25496572 | 0.79 | PPARD (0.38) | PPARDFBP1TSHRIGF2R | |
| SCHEMBL23327455 | 0.78 | — | — | |
| SCHEMBL25495692 | 0.75 | PPARD (0.37) | PPARDTSHR | |
| SCHEMBL25495547 | 0.75 | PPARD (0.37) | PPARDTSHR | |
| SCHEMBL30186546 | 0.75 | PPARD (0.37) | PPARDTSHR | |
| SCHEMBL22614530 | 0.74 | IGF2R (0.53) | FBP1IGF2RAMDHD2 | |
| SCHEMBL25084290 | 0.74 | IGF2R (0.42) | FBP1TSHRIGF2RAMDHD2P2RY14 | |
| SCHEMBL25083634 | 0.74 | IGF2R (0.42) | FBP1TSHRIGF2RAMDHD2P2RY14 | |
| SCHEMBL17176070 | 0.73 | FBP1 (0.34) | PPARDFBP1AMDHD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220259253-A1 | CD73 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2022-08-18 | — | — | US | disclosed |
| US-20220259253-A1 | CD73 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2022-08-18 | — | — | US | disclosed |
| US-11377469-B2 | CD73 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-11377469-B2 | CD73 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20200347090-A1 | CD73 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2020-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347090-A1 | CD73 INHIBITORS | ENTPD5, NT5E, ENTPD1 | PPARD 4037/4885FBP1 567/4885TSHR 3188/4885 |
| US-11377469-B2 | CD73 inhibitors | ENTPD5, NT5E, ENTPD1 | PPARD 4037/4885FBP1 567/4885TSHR 3188/4885 |
| US-20220259253-A1 | CD73 INHIBITORS | ENTPD5, NT5E, ENTPD1 | PPARD 4037/4885FBP1 567/4885TSHR 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.